ASCO 2017 - Advanced SCLC: promising results with nivolumab±ipilimumab

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
  • Takeaway

    • At a maximum tolerated dose of nivolumab (Opdivo) 3 mg/kg every 2 wk (Q2W) or nivolumab 1 mg/kg+ipilimumab (Yervoy) 1 mg/kg Q3W×4 cycles, the pooled ORR was 22% in this phase 1/2 trial of the PD-1 blocking antibody (nivolumab) alone or in combination with the CTLA-4 blocking anti...